NASDAQ:LBRX LB Pharmaceuticals Q4 2025 Earnings Results & Report $37.22 +2.61 (+7.54%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$37.21 -0.01 (-0.03%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. LB Pharmaceuticals met analyst earnings expectations in its Q4 2025 results, released March 26, 2026. The company reported EPS of -$0.45 versus the -$0.45 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 26, 2026TimeAfter Market Closes LB Pharmaceuticals EPS ResultsActual EPS-$0.45Consensus EPS -$0.45Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate1 of last 4 quartersLB Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) LB Pharmaceuticals Q4 2025 Earnings FAQ Did LB Pharmaceuticals beat earnings estimates for Q4 2025? LB Pharmaceuticals (NASDAQ:LBRX) reported earnings of -$0.45 per share for Q4 2025, matching the consensus estimate of -$0.45. The report was announced on Thursday, March 26, 2026. LB Pharmaceuticals Earnings HeadlinesCanaccord Genuity Initiates LB Pharmaceuticals at Buy With $65 Price TargetOctober 9 at 5:31 PM | finance.yahoo.comLB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)October 9 at 5:31 PM | finance.yahoo.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)LB Pharmaceuticals Grants Inducement Equity Awards to New Chief Medical Officer and Chief Financial OfficerOctober 9 at 5:10 PM | quiverquant.comQLB Pharmaceuticals (NASDAQ:LBRX) Stock Lifted to "Strong-Buy" by GuggenheimOctober 7 at 7:54 AM | americanbankingnews.comLB Pharmaceuticals (NASDAQ:LBRX) Stock Falls 5.4% After Analyst DowngradeOctober 7 at 1:21 AM | americanbankingnews.comSee More LB Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like LB Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LB Pharmaceuticals and other key companies, straight to your email. Email Address About LB PharmaceuticalsLB Pharmaceuticals (NASDAQ:LBRX) is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system and neuropsychiatric disorders. The company’s lead product candidate is LB-102, an oral prodrug of amisulpride, an established antipsychotic medicine that is approved in certain countries outside the United States but is not currently approved in the U.S. LB-102 is being developed for the treatment of schizophrenia, with the company seeking to evaluate its potential to address the needs of patients and healthcare providers in the U.S. and other markets. LB Pharmaceuticals’ development activities are centered on advancing this candidate through clinical testing and regulatory review. The company is headquartered in New York and is listed on the Nasdaq under the symbol LBRX. Publicly available information about its broader pipeline, international operations and leadership is limited.View LB Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
